Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
First Claim
Patent Images
1. A method of promoting the production of a human Huntingtin protein lacking a proteolytic caspase-6 cleavage site in a human cell, the method comprising:
- providing a human cell that expresses a human Huntingtin protein comprising a caspase-6 proteolytic cleavage site from a pre-mRNA encoding said protein with an anti-sense oligonucleotide that is directed toward the interior of exon 12 of the human Huntingtin gene;
binds to the pre-mRNA to form a double-stranded nucleic acid complex;
induces partial skipping of exon 12, wherein at least nucleotides 207 to 341 of exon 12 are skipped; and
wherein each nucleotide of the anti-sense oligonucleotide is chemically modified to render the double-stranded nucleic acid complex RNase H resistant, andallowing translation of mRNA produced from said pre-mRNA in the cell to produce an mRNA lacking nucleotides 207 to 341 of exon 12.
1 Assignment
0 Petitions
Accused Products
Abstract
Described are means and methods for removing a proteolytic cleavage site from a protein, the method comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, and allowing translation of mRNA produced from the pre-mRNA.
-
Citations
6 Claims
-
1. A method of promoting the production of a human Huntingtin protein lacking a proteolytic caspase-6 cleavage site in a human cell, the method comprising:
-
providing a human cell that expresses a human Huntingtin protein comprising a caspase-6 proteolytic cleavage site from a pre-mRNA encoding said protein with an anti-sense oligonucleotide that is directed toward the interior of exon 12 of the human Huntingtin gene; binds to the pre-mRNA to form a double-stranded nucleic acid complex; induces partial skipping of exon 12, wherein at least nucleotides 207 to 341 of exon 12 are skipped; and wherein each nucleotide of the anti-sense oligonucleotide is chemically modified to render the double-stranded nucleic acid complex RNase H resistant, and allowing translation of mRNA produced from said pre-mRNA in the cell to produce an mRNA lacking nucleotides 207 to 341 of exon 12. - View Dependent Claims (2, 5)
-
-
3. A method for treating Huntington'"'"'s disease in an individual, the method comprising:
-
administering to an individual in need thereof an anti-sense oligonucleotide directed toward the interior of exon 12 of the human Huntingtin gene that binds to a pre-mRNA produced from the human Huntingtin gene to form a double-stranded nucleic acid complex; and
induces partial skipping of exon 12 of the human Huntingtin gene wherein at least nucleotides 207 to 341 of exon 12 are skipped; andwherein each nucleotide of the anti-sense oligonucleotide is chemically modified to render the double-stranded nucleic acid complex RNase H resistant. - View Dependent Claims (4, 6)
-
Specification